Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Esperion Therapeutics, Inc.

http://www.esperion.com/

Latest From Esperion Therapeutics, Inc.

NewAmsterdam Takes Another Step Toward CETP Inhibitor Success

Positive Phase II data indicate that obicetrapib, a cholesterol-lowering drug licensed from Amgen, could succeed where prior drugs in the class have consistently failed for more than a decade.

Clinical Trials Business Strategies

Stock Watch: Filling In The Blanks In Clinical Trial Result Announcements

If a clinical trial is positive, with safety and efficacy that trounces the competition, why be coy about the details?

Stock Watch Clinical Trials

Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake

The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.

Clinical Trials Cardiovascular

Stock Watch: Pharma Castoffs Sink Without A Trace … Eventually

When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?

Stock Watch Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register